FindTrial
Sign In

Single dose pharmacokinetic study of HP-3060

Single dose pharmacokinetic study of HP-3060 in pediatric patients with allergic rhinitis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080223009
Enrollment
Unknown
Registered
2015-11-10
Start date
2015-11-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

investigational material(s) Generic name etc : HP-3060 (Emedastine fumarate) INN of investigational material : emedastine Therapeutic category code : 269 Other agents for epidermis Dosage and Administ

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients who a diagnosis of allergic rhinitis and symptoms of this condition.

Exclusion criteria

Exclusion criteria: - Patients who have a history of hypersensitivity to any medicines. - Patients who may be affected by blood sampling in the study following blood collection or bleeding within 4 weeks prior to study drug administration.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetics, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026